NMRA is trading at $1.45 (10.1% down) in pre-market, extending recent volatility after its lead depression drug navacaprant failed multiple Phase 3 KOASTAL trials in major depressive disorder.
- The stock remains under significant pressure following a 35% workforce reduction and the disclosure of clinical failures on June 15, 2026.
- Shares continue to be impacted by ongoing legal and investor investigations regarding the company's prior cash runway and trial projections.